| 1 | In Situ
Detection of Individual Classic MHC-I Gene Products in Cancer | 4.2 | 2 | Citations (PDF) |
| 2 | Preclinical mouse models of immune checkpoint inhibitor-associated myocarditis | 8.3 | 7 | Citations (PDF) |
| 3 | Dynamic single-cell systemic immune responses in immunotherapy-treated early-stage HR+ breast cancer patients | 6.4 | 6 | Citations (PDF) |
| 4 | NKG2A Is a Therapeutic Vulnerability in Immunotherapy Resistant MHC-I Heterogeneous Triple-Negative Breast Cancer | 25.1 | 57 | Citations (PDF) |
| 5 | Polygenic risk score for ulcerative colitis predicts immune checkpoint inhibitor-mediated colitis | 13.7 | 30 | Citations (PDF) |
| 6 | Epithelial Expressed B7-H4 Drives Differential Immunotherapy Response in Murine and Human Breast Cancer | 2.8 | 12 | Citations (PDF) |
| 7 | Associations of Immune Checkpoint Predictive Biomarkers (MHC-I and MHC-II) with Clinical and Molecular Features in a Diverse Breast Cancer Cohort | 6.8 | 8 | Citations (PDF) |
| 8 | Efficacy and safety of immune checkpoint inhibitors in young adults with metastatic melanoma | 4.9 | 14 | Citations (PDF) |
| 9 | Corticosteroids and Cancer Immunotherapy | 6.8 | 145 | Citations (PDF) |
| 10 | Peripheral T-cell receptor repertoire dynamics in small cell lung cancer | 2.0 | 8 | Citations (PDF) |
| 11 | Convolutional neural network for biomarker discovery for triple negative breast cancer with RNA sequencing data | 3.2 | 5 | Citations (PDF) |
| 12 | STING-activating nanoparticles normalize the vascular-immune interface to potentiate cancer immunotherapy | 13.4 | 119 | Citations (PDF) |
| 13 | Polycomb repressor complex 2 suppresses interferon-responsive MHC-II expression in melanoma cells and is associated with anti-PD-1 resistance 2023, 11, e007736 | | 20 | Citations (PDF) |
| 14 | Immune-checkpoint inhibitors: long-term implications of toxicity | 70.7 | 882 | Citations (PDF) |
| 15 | Mechanisms of MHC-I Downregulation and Role in Immunotherapy Response | 4.9 | 262 | Citations (PDF) |
| 16 | Peripheral Blood Monocyte Abundance Predicts Outcomes in Patients with Breast Cancer | 2.8 | 11 | Citations (PDF) |
| 17 | Epigenetic Repression of STING by MYC Promotes Immune Evasion and Resistance to Immune Checkpoint Inhibitors in Triple-Negative Breast Cancer | 4.2 | 58 | Citations (PDF) |
| 18 | Combined Dusp4 and p53 loss with Dbf4 amplification drives tumorigenesis via cell cycle restriction and replication stress escape in breast cancer | 4.7 | 10 | Citations (PDF) |
| 19 | T cells specific for α-myosin drive immunotherapy-related myocarditis | 37.9 | 307 | Citations (PDF) |
| 20 | Multiomics in primary and metastatic breast tumors from the AURORA US network finds microenvironment and epigenetic drivers of metastasis | 22.5 | 47 | Citations (PDF) |
| 21 | Hydroxychloroquine as Pre-exposure Prophylaxis for Coronavirus Disease 2019 (COVID-19) in Healthcare Workers: A Randomized Trial | 5.2 | 116 | Citations (PDF) |
| 22 | A Genetic Mouse Model Recapitulates Immune Checkpoint Inhibitor–Associated Myocarditis and Supports a Mechanism-Based Therapeutic Intervention | 25.1 | 264 | Citations (PDF) |
| 23 | Nanoparticle delivery improves the pharmacokinetic properties of cyclic dinucleotide STING agonists to open a therapeutic window for intravenous administration | 11.0 | 113 | Citations (PDF) |
| 24 | Automated Dissection Protocol for Tumor Enrichment in Low Tumor Content Tissues | 0.3 | 2 | Citations (PDF) |
| 25 | Progesterone promotes immunomodulation and tumor development in the murine mammary gland 2021, 9, e001710 | | 28 | Citations (PDF) |
| 26 | Breast cancer resistance mechanisms: challenges to immunotherapy | 2.3 | 39 | Citations (PDF) |
| 27 | RNA-Sequencing Reveals a Distinct Transcriptomic Signature for Giant Cell Myocarditis and Identifies Novel Druggable Targets | 13.1 | 10 | Citations (PDF) |
| 28 | Tumor-Specific Major Histocompatibility-II Expression Predicts Benefit to Anti–PD-1/L1 Therapy in Patients With HER2-Negative Primary Breast Cancer | 6.8 | 87 | Citations (PDF) |
| 29 | Framework for Implementing and Tracking a Molecular Tumor Board at a National Cancer Institute–Designated Comprehensive Cancer Center | 3.4 | 17 | Citations (PDF) |
| 30 | Triple-Negative Breast Cancer | 1.8 | 30 | Citations (PDF) |
| 31 | Artificial image objects for classification of breast cancer biomarkers with transcriptome sequencing data and convolutional neural network algorithms | 4.7 | 11 | Citations (PDF) |
| 32 | Multi-omics analysis identifies therapeutic vulnerabilities in triple-negative breast cancer subtypes | 13.7 | 239 | Citations (PDF) |
| 33 | Pharmacological Activation of cGAS for Cancer Immunotherapy | 4.9 | 24 | Citations (PDF) |
| 34 | Multimodal Multiplexed Immunoimaging with Nanostars to Detect Multiple Immunomarkers and Monitor Response to Immunotherapies | 15.3 | 61 | Citations (PDF) |
| 35 | Immune checkpoint inhibitor toxicities: systems-based approaches to improve patient care and research | 27.4 | 100 | Citations (PDF) |
| 36 | Changes in Peripheral and Local Tumor Immunity after Neoadjuvant Chemotherapy Reshape Clinical Outcomes in Patients with Breast Cancer | 6.8 | 56 | Citations (PDF) |
| 37 | Progesterone receptor promotes degradation of STAT2 to inhibit the interferon response in breast cancer | 5.4 | 21 | Citations (PDF) |
| 38 | 2. Large structural variations in inflammatory breast cancer identifies possible pathognomonic alterations | 0.6 | 0 | Citations (PDF) |
| 39 | Evolving insights into the mechanisms of toxicity associated with immune checkpoint inhibitor therapy | 2.5 | 54 | Citations (PDF) |
| 40 | Targeting MYCN-expressing triple-negative breast cancer with BET and MEK inhibitors | 12.5 | 67 | Citations (PDF) |
| 41 | The path to a better biomarker: application of a risk management framework for the implementation of PD‐L1 and TILs as immuno‐oncology biomarkers in breast cancer clinical trials and daily practice | 4.9 | 195 | Citations (PDF) |
| 42 | Potent STING activation stimulates immunogenic cell death to enhance antitumor immunity in neuroblastoma 2020, 8, e000282 | | 163 | Citations (PDF) |
| 43 | MEK activation modulates glycolysis and supports suppressive myeloid cells in TNBC | 5.4 | 37 | Citations (PDF) |
| 44 | A tumor-intrinsic PD-L1/NLRP3 inflammasome signaling pathway drives resistance to anti–PD-1 immunotherapy | 10.6 | 228 | Citations (PDF) |
| 45 | A case report of clonal EBV-like memory CD4+ T cell activation in fatal checkpoint inhibitor-induced encephalitis | 33.0 | 170 | Citations (PDF) |
| 46 | Two may be better than one: PD-1/PD-L1 blockade combination approaches in metastatic breast cancer | 6.4 | 67 | Citations (PDF) |
| 47 | Biomarker Predictors for Immunotherapy Benefit in Breast: Beyond PD-L1 | 0.8 | 10 | Citations (PDF) |
| 48 | If we build it they will come: targeting the immune response to breast cancer | 6.4 | 182 | Citations (PDF) |
| 49 | PIK3CA and MAP3K1 alterations imply luminal A status and are associated with clinical benefit from pan-PI3K inhibitor buparlisib and letrozole in ER+ metastatic breast cancer | 6.4 | 45 | Citations (PDF) |
| 50 | Endosomolytic polymersomes increase the activity of cyclic dinucleotide STING agonists to enhance cancer immunotherapy | 32.2 | 641 | Citations (PDF) |
| 51 | Neurologic toxicity associated with immune checkpoint inhibitors: a pharmacovigilance study 2019, 7, | | 344 | Citations (PDF) |
| 52 | Tumor genomic alterations in severe-combined immunodeficiency bare-lymphocyte syndrome genes are associated with high mutational burden and disproportional neo-antigen rates 2019, 7, | | 3 | Citations (PDF) |
| 53 | Aberrant FGFR signaling mediates resistance to CDK4/6 inhibitors in ER+ breast cancer | 13.7 | 368 | Citations (PDF) |
| 54 | Severe Epididymo-Orchitis and Encephalitis Complicating Anti-PD-1 Therapy | 3.4 | 54 | Citations (PDF) |
| 55 | Biomarkers for Immunotherapy Toxicity: Are Cytokines the Answer? | 6.8 | 41 | Citations (PDF) |
| 56 | Treatment-Induced Tumor Cell Apoptosis and Secondary Necrosis Drive Tumor Progression in the Residual Tumor Microenvironment through MerTK and IDO1 | 3.8 | 81 | Citations (PDF) |
| 57 | Biological Consequences of MHC-II Expression by Tumor Cells in Cancer | 6.8 | 454 | Citations (PDF) |
| 58 | Extended Adjuvant Therapy with Neratinib Plus Fulvestrant Blocks ER/HER2 Crosstalk and Maintains Complete Responses of ER+/HER2+ Breast Cancers: Implications to the ExteNET Trial | 6.8 | 42 | Citations (PDF) |
| 59 | DNA methyltransferase inhibition upregulates MHC-I to potentiate cytotoxic T lymphocyte responses in breast cancer | 13.7 | 271 | Citations (PDF) |
| 60 | PIK3CA
C2 Domain Deletions Hyperactivate Phosphoinositide 3-kinase (PI3K), Generate Oncogene Dependence, and Are Exquisitely Sensitive to PI3K
α
Inhibitors | 6.8 | 33 | Citations (PDF) |
| 61 | Effect of CCL5 expression in the recruitment of immune cells in triple negative breast cancer | 3.4 | 119 | Citations (PDF) |
| 62 | Melanoma response to anti-PD-L1 immunotherapy requires JAK1 signaling, but not JAK2 | 5.4 | 77 | Citations (PDF) |
| 63 | Emerging biomarkers for cancer immunotherapy in melanoma | 13.7 | 52 | Citations (PDF) |
| 64 | Cardiovascular toxicities associated with immune checkpoint inhibitors: an observational, retrospective, pharmacovigilance study | 27.4 | 1,144 | Citations (PDF) |
| 65 | Fatal Toxic Effects Associated With Immune Checkpoint Inhibitors | 14.3 | 2,541 | Citations (PDF) |
| 66 | Quantitative Spatial Profiling of PD-1/PD-L1 Interaction and HLA-DR/IDO-1 Predicts Improved Outcomes of Anti–PD-1 Therapies in Metastatic Melanoma | 6.8 | 155 | Citations (PDF) |
| 67 | Phase II study of ruxolitinib, a selective JAK1/2 inhibitor, in patients with metastatic triple-negative breast cancer | 6.4 | 131 | Citations (PDF) |
| 68 | Tumor-specific MHC-II expression drives a unique pattern of resistance to immunotherapy via LAG-3/FCRL6 engagement | 5.4 | 166 | Citations (PDF) |
| 69 | Therapeutic potential of DNA methyltransferase inhibitors with immune checkpoint inhibitor therapy in breast cancer | 2.2 | 10 | Citations (PDF) |
| 70 | A Phase Ib Study of Alpelisib (BYL719), a PI3Kα-Specific Inhibitor, with Letrozole in ER+/HER2− Metastatic Breast Cancer | 6.8 | 304 | Citations (PDF) |
| 71 | Quantitative Mass Spectrometry Analysis of PD-L1 Protein Expression, N-glycosylation and Expression Stoichiometry with PD-1 and PD-L2 in Human Melanoma | 3.0 | 72 | Citations (PDF) |
| 72 | Deep exploration of the immune infiltrate and outcome prediction in testicular cancer by quantitative multiplexed immunohistochemistry and gene expression profiling | 5.4 | 74 | Citations (PDF) |
| 73 | Key Survival Factor, Mcl-1, Correlates with Sensitivity to Combined Bcl-2/Bcl-xL Blockade | 3.1 | 50 | Citations (PDF) |
| 74 | MYC and MCL1 Cooperatively Promote Chemotherapy-Resistant Breast Cancer Stem Cells via Regulation of Mitochondrial Oxidative Phosphorylation | 25.2 | 609 | Citations (PDF) |
| 75 | Agonist immunotherapy restores T cell function following MEK inhibition improving efficacy in breast cancer | 13.7 | 117 | Citations (PDF) |
| 76 | Association of FGFR1 with ERα Maintains Ligand-Independent ER Transcription and Mediates Resistance to Estrogen Deprivation in ER+ Breast Cancer | 6.8 | 124 | Citations (PDF) |
| 77 | Genomic profiling of ER
+
breast cancers after short-term estrogen suppression reveals alterations associated with endocrine resistance | 12.5 | 114 | Citations (PDF) |
| 78 | Assessing Tumor-Infiltrating Lymphocytes in Solid Tumors: A Practical Review for Pathologists and Proposal for a Standardized Method from the International Immuno-Oncology Biomarkers Working Group: Part 2: TILs in Melanoma, Gastrointestinal Tract Carcinomas, Non–Small Cell Lung Carcinoma and Mesothelioma, Endometrial and Ovarian Carcinomas, Squamous Cell Carcinoma of the Head and Neck, Genitourinary Carcinomas, and Primary Brain Tumors | 2.3 | 744 | Citations (PDF) |
| 79 | Assessing Tumor-infiltrating Lymphocytes in Solid Tumors: A Practical Review for Pathologists and Proposal for a Standardized Method From the International Immunooncology Biomarkers Working Group: Part 1: Assessing the Host Immune Response, TILs in Invasive Breast Carcinoma and Ductal Carcinoma In Situ, Metastatic Tumor Deposits and Areas for Further Research | 2.3 | 637 | Citations (PDF) |
| 80 | ErbB3 drives mammary epithelial survival and differentiation during pregnancy and lactation | 4.7 | 26 | Citations (PDF) |
| 81 | Clinical Response to Anti–Programmed Death 1 After Response and Subsequent Progression on Anti–Programmed Death Ligand 1 Therapy | 1.9 | 3 | Citations (PDF) |
| 82 | Comparative analysis of the GNAQ,GNA11,SF3B1, and EIF1AX driver mutations in melanoma and across the cancer spectrum | 2.8 | 23 | Citations (PDF) |
| 83 | Triple-negative breast cancer: challenges and opportunities of a heterogeneous disease | 70.7 | 2,711 | Citations (PDF) |
| 84 | Targeted Next Generation Sequencing Identifies Markers of Response to PD-1 Blockade | 4.2 | 469 | Citations (PDF) |
| 85 | Melanoma-specific MHC-II expression represents a tumour-autonomous phenotype and predicts response to anti-PD-1/PD-L1 therapy | 13.7 | 545 | Citations (PDF) |
| 86 | A prognostic signature based on three-genes expression in triple-negative breast tumours with residual disease | 4.3 | 54 | Citations (PDF) |
| 87 | Triple-negative breast cancers with amplification of JAK2 at the 9p24 locus demonstrate JAK2-specific dependence | 12.5 | 130 | Citations (PDF) |
| 88 | Fulminant Myocarditis with Combination Immune Checkpoint Blockade | 34.5 | 2,163 | Citations (PDF) |
| 89 | EPHA2 Blockade Overcomes Acquired Resistance to EGFR Kinase Inhibitors in Lung Cancer | 3.8 | 119 | Citations (PDF) |
| 90 | RAS/MAPK Activation Is Associated with Reduced Tumor-Infiltrating Lymphocytes in Triple-Negative Breast Cancer: Therapeutic Cooperation Between MEK and PD-1/PD-L1 Immune Checkpoint Inhibitors | 6.8 | 487 | Citations (PDF) |
| 91 | Kinome-wide Functional Screen Identifies Role of PLK1 in Hormone-Independent, ER-Positive Breast Cancer | 3.8 | 59 | Citations (PDF) |
| 92 | PIK3CA mutations in Peruvian patients with HER2-amplified and triple negative non-metastatic breast cancers | 0.8 | 22 | Citations (PDF) |
| 93 | Molecular Profiling of the Residual Disease of Triple-Negative Breast Cancers after Neoadjuvant Chemotherapy Identifies Actionable Therapeutic Targets | 25.1 | 456 | Citations (PDF) |
| 94 | Emergence of Constitutively Active Estrogen Receptor-α Mutations in Pretreated Advanced Estrogen Receptor–Positive Breast Cancer | 6.8 | 635 | Citations (PDF) |
| 95 | Enabling a Genetically Informed Approach to Cancer Medicine: A Retrospective Evaluation of the Impact of Comprehensive Tumor Profiling Using a Targeted Next-Generation Sequencing Panel | 3.4 | 102 | Citations (PDF) |
| 96 | PIK3CA mutations in androgen receptor-positive triple negative breast cancer confer sensitivity to the combination of PI3K and androgen receptor inhibitors | 4.7 | 309 | Citations (PDF) |
| 97 | The genomic map of breast cancer: which roads lead to better targeted therapies? | 4.7 | 10 | Citations (PDF) |
| 98 | Activation of MAPK Pathways due to DUSP4 Loss Promotes Cancer Stem Cell-like Phenotypes in Basal-like Breast Cancer | 3.8 | 150 | Citations (PDF) |
| 99 | TGF-β inhibition enhances chemotherapy action against triple-negative breast cancer | 10.6 | 563 | Citations (PDF) |
| 100 | The receptor tyrosine kinase ErbB3 maintains the balance between luminal and basal breast epithelium | 7.5 | 72 | Citations (PDF) |
| 101 | Oncogenic Ras and B-Raf Proteins Positively Regulate Death Receptor 5 Expression through Co-activation of ERK and JNK Signaling | 2.2 | 39 | Citations (PDF) |
| 102 | Profiling of residual breast cancers after neoadjuvant chemotherapy identifies DUSP4 deficiency as a mechanism of drug resistance | 33.0 | 246 | Citations (PDF) |
| 103 | Phosphatidylinositol 3-Kinase and Antiestrogen Resistance in Breast Cancer | 16.9 | 401 | Citations (PDF) |
| 104 | Ovarian carcinoma as a surrogate tumor for lung adenocarcinomas in evaluating the chemo-stability of a gene expression signature | 4.1 | 2 | Citations (PDF) |
| 105 | MEK and EGFR inhibition demonstrate synergistic activity in EGFR-dependent NSCLC | 4.1 | 37 | Citations (PDF) |
| 106 | A gene expression predictor of response to EGFR-targeted therapy stratifies progression-free survival to cetuximab in KRAS wild-type metastatic colorectal cancer | 2.9 | 27 | Citations (PDF) |
| 107 | Deregulation of DUSP activity in EGFR-mutant lung cancer cell lines contributes to sustained ERK1/2 signaling | 2.1 | 27 | Citations (PDF) |
| 108 | MUC1 is a downstream target of STAT3 and regulates lung cancer cell survival and invasion | 3.8 | 21 | Citations (PDF) |
| 109 | Gene expression patterns that predict sensitivity to epidermal growth factor receptor tyrosine kinase inhibitors in lung cancer cell lines and human lung tumors | 3.3 | 66 | Citations (PDF) |
| 110 | MEK inhibition activates STAT signaling to increase breast cancer immunogenicity via MHC-I expression 0, , | | 18 | Citations (PDF) |
| 111 | Molecular analysis of immune checkpoint inhibitor associated erythema nodosum-like toxicity | 4.9 | 3 | Citations (PDF) |
| 112 | Tumor-specific major histocompatibility-II expression predicts pathological complete response to atezolizumab combined to chemotherapy in triple-negative breast cancer | 6.4 | 1 | Citations (PDF) |
| 113 | The Impact of
JAK1
Pathogenic Variants and MHC-I Expression on Response to Immune Checkpoint Inhibition in Endometrial Cancer | 6.8 | 1 | Citations (PDF) |
| 114 | [Expression of Concern] MUC1 is a downstream target of STAT3 and regulates lung cancer cell survival and invasion | 3.8 | 0 | Citations (PDF) |
| 115 | CXCR6
+
T Cells Drive Immune Checkpoint Inhibitor Myocarditis | 18.0 | 7 | Citations (PDF) |
| 116 | Topoisomerase I inhibitor antibody–drug conjugates in breast cancer: the relevance of the DNA damage response to resistance, response, and combination treatment strategies | 2.3 | 0 | Citations (PDF) |
| 117 | Abstract LB168: Advancing peptide-MHC binding prediction with JANUS through iterative multi-allele deconvolution and ensemble deep learning | 3.8 | 0 | Citations (PDF) |
